Researcher Next
Create account
← Back to directory

Adam Płużański

Researcher Next ID · RN-014009

Researcher · Medicine

National Institute of Oncology

, Hungary

Sign in to saveSign in to claim
Not currently recruitingFunding unknown
Works count
120
Citation count
17,382
H-index
27
i10-index
39

Research interests

Medicine
Lung Cancer Treatments and Mutations
Cancer Immunotherapy and Biomarkers
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Colorectal Cancer Treatments and Studies

Publications

  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    Journal of Clinical Oncology · 2021 · 10.1200/jco.20.01605

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1801946

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

    The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30608-3

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

    Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.74.3062

  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

    New England Journal of Medicine · 2015 · 10.1056/nejmoa1504627

Current projects

    No projects listed.